All Content Clinical Leader

  1. Open-Label Study Assessing Relative And Absolute Bioavailability 1/26/2026

    Consistent absorption across different formulations and dietary conditions ensures stable therapeutic exposure. This flexibility simplifies patient dosing schedules and supports manufacturing transitions.

  2. What CROs Do Right Isn't Always Obvious To Research Sites 1/26/2026

    CROs are doing many things right. But it's when that right thing is understood — not just executed — that the impact becomes far greater than compliance alone.

  3. How Gilead Includes Patients Most Affected By HIV In Its PrEP Trials 1/26/2026

    VP of Clinical Development, HIV, Moupali Das shares how the sponsor approaches diverse participant recruitment and enrollment, highlighting the importance of early demographic research and careful, intentional PI selection.

  4. Improving The eCOA Experience 1/25/2026

    Discover how template-driven builds and reuse can slash eCOA timelines by 50% while solving the licensing and translation hurdles that delay First Patient In.

  5. When Clinical Trials Don't Stop For War 1/23/2026

    When war halted clinical trials in Ukraine, sites adapted instead of shutting down. Dr. Anna Titkova explains how patients, investigators, and sponsors kept research moving when conditions were anything but stable.

  6. 3 Clinical Research Attorneys Talk 2026 Trends 1/23/2026

    Three life sciences legal experts share what they see happening in the year ahead — and what should remain firmly in the past. 

  7. Serbia: Europe's Emerging Clinical Trial Powerhouse 1/22/2026

    Discover why Serbia is becoming a top strategic choice for sponsors, including details of the country's strengths in key therapeutic areas, streamlined processes, and operational advantages.

  8. Changing The Clinical Feasibility Game With AI 1/22/2026

    AI is only as good as the data it’s built upon. Our customized AI platforms are constructed on a foundation of trustworthy, carefully curated data to produce detailed, expert-driven responses.

  9. The "One-Trial" Trap: Why 2026's FDA Efficiency Push Actually Doubles Your Operational Risk 1/22/2026

    When it comes to the FDA's new "one-trial" shift, researcher Johnathon Anderson, Ph.D., warns: Do not confuse efficiency with leniency. Here, Anderson offers three factors to consider when adapting to new FDA trial expectations.

  10. Common Issues And Trends In Clinical Research Vendor Qualification 1/21/2026

    Discover the biggest challenges in vendor qualification, including this one misalignment that affected more than half of surveyed respondents.